Forecast Period | 2026-2030 |
Market Size (2024) | USD 450.25 Million |
Market Size (2030) | USD 710.17 Million |
CAGR (2025-2030) | 7.85% |
Fastest Growing Segment | Tumor Necrosis Factor (TNF)-Inhibitors |
Largest Market | Kanto |
Market Overview
Japan
Psoriasis Drugs Market was valued at USD 450.25 billion in 2024 and is
anticipated to project impressive growth in the forecast period with a CAGR of 7.85%
through 2030. The Japan Psoriasis Drugs Market is a rapidly evolving segment
within the pharmaceutical industry, distinguished by its expanding patient
base, innovative treatment options, and notable growth potential. Recent years
have seen considerable market expansion, fueled by increasing disease
prevalence, technological advancements in treatment, and rising healthcare
expenditures. This growth trajectory is expected to continue as new therapies
become available and patient access improves.
Despite
challenges such as high drug costs and regulatory obstacles, the market offers
significant opportunities for growth and innovation. Major players are actively
developing new therapies to address unmet needs, driving further market
expansion and advancement in psoriasis treatment in Japan.
Key Market Drivers
Rising Prevalence of Psoriasis
The
growing number of individuals diagnosed with psoriasis directly boosts the
demand for treatment options. As the prevalence of psoriasis rises, more
patients seek effective therapies to manage their condition. The prevalence
of self-reported psoriasis (PsO) and/or psoriatic arthritis (PsA) in the
Japanese UPLIFT subgroup (2%) was notably higher compared to the estimated
prevalence of diagnosed PsO and/or PsA reported in a nationwide study using the
Japanese national claims database (0.3%). However, this prevalence was lower
than that observed in the overall UPLIFT survey. This increased demand
translates into a larger market for psoriasis drugs, as pharmaceutical
companies and healthcare providers focus on developing and delivering new and
improved treatment options. An increasing prevalence of psoriasis expands the
target patient population for psoriasis drugs. This larger patient pool
includes individuals with varying degrees of the disease, from mild to severe.
Pharmaceutical companies and healthcare providers are motivated to address the
needs of this diverse patient population, leading to the development of a wider
range of therapies, including biologics, systemic drugs, and topical
treatments.
The
rising prevalence of psoriasis creates substantial market opportunities for
pharmaceutical companies. Companies see potential for growth in both
established and emerging markets. This encourages investment in research and
development to innovate new treatments and improve existing ones. Additionally,
the increased patient base offers opportunities for companies to expand their
market share and revenue through both new drug launches and extended
indications for existing therapies. As the prevalence of psoriasis rises, there
is a heightened focus on drug development and innovation to address the growing
patient needs. The pharmaceutical industry is incentivized to invest in the
research and development of novel therapies, including targeted biologics and
personalized medicine approaches. This focus on innovation leads to the
introduction of more effective and efficient treatments, further driving market
growth. The growing number of psoriasis cases contributes to increased
healthcare expenditure. Government and private sector spending on psoriasis
management, including drug therapies and healthcare services, rises in response
to the higher patient burden. This increased expenditure supports market growth
by facilitating the availability and affordability of psoriasis drugs and
enabling access to advanced treatments.
The
rising prevalence of psoriasis raises awareness among healthcare professionals
and the general public. Greater awareness leads to improved diagnosis rates, as
healthcare providers are more likely to identify and diagnose psoriasis cases
earlier. Enhanced diagnostic capabilities contribute to the earlier initiation
of treatment, driving demand for psoriasis drugs and promoting market growth. A
higher prevalence of psoriasis often leads to increased patient advocacy and
support. Patient advocacy groups work to raise awareness, provide education,
and influence healthcare policies. Their efforts help to highlight the need for
effective treatments and support the development of new therapies, driving
growth in the psoriasis drugs market by ensuring that patient needs are met and
that treatments are widely accessible. The rising prevalence of psoriasis can
lead to greater government and health insurance support for psoriasis
treatments. Governments may implement policies to subsidize the cost of
psoriasis drugs or provide funding for research and development. Health insurance
providers may expand coverage for psoriasis treatments, making medications more
accessible to patients and stimulating market growth.
Advancements in Treatment
Technologies
Recent
innovations in psoriasis treatment technologies have led to the development of
new therapeutic classes that address the limitations of previous treatments.
The advent of biologics, such as TNF-alpha inhibitors, IL-17 inhibitors, and
IL-23 inhibitors, has revolutionized psoriasis management. These drugs target
specific cytokines involved in the inflammatory process, offering more precise
and effective treatment options. The availability of these advanced therapies
caters to patients with moderate to severe psoriasis and drives market
expansion. New oral small molecules, like Janus kinase (JAK) inhibitors, have
emerged as viable alternatives to biologics. These medications offer
convenience and effectiveness, expanding the range of treatment options
available to patients and enhancing market growth.
Advancements
in drug delivery systems improve the efficacy, convenience, and adherence to
psoriasis treatments. Innovations in long-acting injectable formulations reduce
the frequency of administration. These formulations enhance patient compliance
by minimizing the need for frequent visits to healthcare providers, thereby
increasing the adoption of advanced therapies. New topical formulations, such
as novel delivery systems for corticosteroids and vitamin D analogs, improve
drug penetration and efficacy. These advancements make topical treatments more
effective and appealing to patients, contributing to market growth. The
development of user-friendly injection devices and auto-injectors simplifies
the administration of biologics. These devices enhance patient convenience and
adherence, supporting the growth of the psoriasis drugs market. The shift
towards personalized medicine in psoriasis treatment is driving market growth
by tailoring therapies to individual patient needs. Advances in genomics and
biomarker research enable the identification of specific genetic markers and
disease subtypes. Personalized treatment plans based on these insights allow
for more targeted and effective therapies, improving patient outcomes and driving
demand for advanced treatments. Personalized medicine approaches allow for the
customization of treatment regimens based on patient characteristics, such as
disease severity, comorbidities, and previous treatment responses. This
tailored approach ensures that patients receive the most appropriate and
effective therapies, promoting market growth.
Advancements
in diagnostic technologies contribute to the growth of the psoriasis drugs
market by enabling early and accurate diagnosis. New imaging technologies, such
as high-resolution skin imaging and laser-based methods, provide detailed
visualization of psoriasis lesions. Accurate diagnosis and disease monitoring
facilitate timely treatment interventions and drive demand for effective
psoriasis drugs. The discovery of novel biomarkers associated with psoriasis
helps in diagnosing the condition more precisely and predicting treatment
responses. Enhanced diagnostic capabilities lead to better patient
stratification and management, contributing to market growth. Digital health
technologies are transforming psoriasis management and driving market growth
through improved patient engagement and treatment adherence. Mobile health
applications allow patients to track their symptoms, medication adherence, and
treatment outcomes. These apps provide valuable data to healthcare providers
and facilitate personalized treatment adjustments, enhancing the effectiveness
of psoriasis therapies and fostering market growth. Telemedicine platforms
enable remote consultations and monitoring of psoriasis patients. This
technology expands access to care, particularly in rural or underserved areas,
and promotes the use of advanced treatments by making them more accessible to a
broader patient population.
Ongoing
investment in research and development (R&D) drives innovation in psoriasis
treatment technologies, contributing to market growth. Increased investment in
R&D by pharmaceutical companies leads to the discovery of new treatment
modalities and improvements in existing therapies. This investment supports the
development of cutting-edge treatments and drives market expansion. Collaboration
between academic institutions, research organizations, and the pharmaceutical
industry accelerates the development of novel therapies and technologies. These
collaborative efforts foster innovation and contribute to the growth of the
psoriasis drugs market. Advancements in treatment technologies drive the growth
of the Japan Psoriasis Drugs Market by introducing new therapeutic classes,
enhancing drug delivery systems, embracing personalized medicine approaches,
improving diagnostic technologies, integrating digital health solutions, and
fostering increased R&D investment. These technological advancements
enhance the effectiveness, convenience, and accessibility of psoriasis
treatments, leading to greater market demand and continued growth.
Increased Healthcare
Expenditure and Access
Increased
government spending on healthcare significantly impacts the psoriasis drugs
market by making advanced treatments more accessible. In 2021, Japan’s
national medical care expenses reached approximately 45 trillion Japanese yen,
marking an increase from about 39.2 trillion Japanese yen in fiscal year 2012.
The Japanese government’s commitment to expanding its healthcare budget
directly supports the availability of psoriasis treatments. This includes
funding for new drug development, subsidizing the cost of expensive biologics,
and supporting research into new therapies. Government subsidies and favorable
reimbursement policies reduce the financial burden on patients for psoriasis
treatments. By covering a larger portion of treatment costs, these policies
enhance patient access to advanced medications and stimulate market growth. Improvements
in health insurance coverage contribute to market growth by enhancing patient
access to psoriasis treatments. Health insurance providers are increasingly
covering newer and more expensive psoriasis drugs, including biologics and
advanced topical treatments. This expanded coverage ensures that a larger
number of patients can afford and access effective therapies. Expanded
insurance coverage reduces out-of-pocket expenses for patients, making it
easier for them to adhere to prescribed treatments. Lower financial barriers
encourage patients to seek treatment and follow prescribed regimens,
contributing to higher market demand.
Enhanced
access to specialized dermatological care drives market growth by facilitating
timely and accurate treatment of psoriasis. The expansion of healthcare
infrastructure and resources results in a greater number of dermatologists and
specialized clinics. Improved access to these specialists ensures that more
patients receive appropriate and timely psoriasis diagnosis and treatment. The
integration of telemedicine services enhances access to specialized care for
patients in remote or underserved areas. Telemedicine allows patients to
consult with dermatologists and receive prescriptions for advanced psoriasis
treatments without needing to travel long distances. Advancements in healthcare
infrastructure contribute to the growth of the psoriasis drugs market by
improving the overall quality and accessibility of care. The development and
upgrading of healthcare facilities, including hospitals and outpatient clinics,
provide better environments for the diagnosis and treatment of psoriasis.
State-of-the-art facilities support the use of advanced treatment technologies
and enhance patient care. Increased investment in health technology, such as
electronic health records (EHR) systems and diagnostic tools, improves the
efficiency and effectiveness of psoriasis management. Better health technology
supports accurate diagnosis and personalized treatment plans, driving market
growth.
Increased
healthcare expenditure often leads to higher levels of patient awareness and
engagement, which drives market growth. Government and healthcare organizations
conduct public health campaigns to raise awareness about psoriasis and
available treatment options. These campaigns educate patients about the
importance of seeking treatment and adhering to prescribed therapies, increasing
demand for psoriasis drugs. Enhanced healthcare spending supports patient
education and support programs that help individuals manage their condition
effectively. These programs improve patient adherence to treatment plans and
foster greater utilization of available therapies. Economic growth and improved
standards of living in Japan contribute to increased healthcare expenditure and
access. As the economy grows and living standards improve, patients are more
likely to afford out-of-pocket expenses for advanced psoriasis treatments.
Higher disposable income supports the adoption of newer therapies and drives
market growth. Economic prosperity leads to increased investment in healthcare
infrastructure and services. This investment enhances access to high-quality
care and advanced treatments, contributing to the expansion of the psoriasis
drugs market.
Download Free Sample Report
Key Market Challenges
Regulatory and Market Access
Barriers
Regulatory
hurdles and market access issues present significant challenges to the growth
of the psoriasis drugs market. The
regulatory approval process for new psoriasis drugs in Japan can be lengthy and
rigorous. Drug developers must navigate complex regulatory requirements and
demonstrate robust clinical evidence to gain approval, which can delay market
entry and affect the availability of innovative treatments.
Japan's
Pharmaceuticals and Medical Devices Agency (PMDA) requires extensive clinical
evidence to support the safety and efficacy of new drugs. Meeting these high
standards can be resource-intensive and time-consuming for pharmaceutical
companies. Even after gaining regulatory approval, drugs may face delays in
market access due to negotiation processes with healthcare authorities and
insurance providers. These delays can impact the timely availability of new
treatments and influence market dynamics.
Limited Patient Awareness and
Education
Limited
patient awareness and education about psoriasis and available treatments can
restrict market growth by affecting treatment uptake. Many patients may not be fully aware of
psoriasis treatments or the benefits of advanced therapies. This lack of
awareness can lead to underutilization of available treatments and delayed
diagnosis, impacting market demand.
There
may be gaps in patient education regarding the management of psoriasis and the
importance of adhering to prescribed therapies. Addressing these educational
gaps is crucial for improving patient outcomes and fostering market growth. Psoriasis
is often associated with social stigma and psychological distress. Patients may
be reluctant to seek treatment due to embarrassment or fear of discrimination,
which can limit market growth and affect treatment adherence.
Key Market Trends
Advancements in Biologic
Therapies
Biologic
therapies represent a significant trend in the treatment of psoriasis, driven
by continuous innovation and development of new biologic drugs. The development
of next-generation biologics, such as IL-17 inhibitors and IL-23 inhibitors,
offers more targeted and effective treatment options. These biologics provide
improved efficacy and safety profiles, addressing the unmet needs of patients
who do not respond well to traditional therapies.
Advances
in genomics and molecular biology are paving the way for personalized medicine
approaches in psoriasis treatment. By understanding individual genetic profiles
and disease mechanisms, healthcare providers can tailor biologic therapies to
achieve optimal outcomes for each patient. The introduction of long-acting
biologic formulations reduces the frequency of administration, enhancing
patient convenience and adherence to treatment. These formulations are
particularly beneficial for chronic conditions like psoriasis, where long-term
management is crucial.
Integration of Digital Health
Technologies
The
integration of digital health technologies is revolutionizing the management of
psoriasis, driving market growth through improved patient care and engagement. Telemedicine platforms enable remote
consultations and monitoring of psoriasis patients, enhancing access to
dermatological care. This is particularly important in Japan, where geographic
barriers can limit access to specialized healthcare providers.
Mobile
health applications offer tools for tracking symptoms, medication adherence,
and treatment outcomes. These apps empower patients to manage their condition
more effectively and provide valuable data to healthcare providers for
personalized treatment adjustments. AI-driven tools assist in diagnosing and
monitoring psoriasis by analyzing skin images and clinical data. AI algorithms
can predict disease flares and treatment responses, enabling proactive and
timely interventions.
Increased Focus on
Patient-Centric Care
There
is a growing emphasis on patient-centric care in the psoriasis treatment
paradigm, which is reshaping the market by prioritizing patient needs and
experiences. Comprehensive education and
support programs help patients understand their condition and treatment
options. These programs enhance patient engagement, improve adherence to
therapies, and lead to better health outcomes.
Recognizing
the impact of psoriasis on overall well-being, there is an increasing focus on
holistic treatment approaches that address both physical and psychological
aspects of the disease. Integrating mental health support and lifestyle
interventions with medical treatment provides a more comprehensive care model. Patient
advocacy groups are playing a crucial role in shaping healthcare policies and
treatment guidelines. Their involvement ensures that patient perspectives are
considered in decision-making processes, leading to more patient-centric care
and better alignment of treatment strategies with patient needs.
Segmental Insights
Therapeutic Class Insights
Based
on the category of Therapeutic Class, the tumor necrosis factor
(TNF)-inhibitors segment emerged as the dominant in the market for Japan
Psoriasis Drugs in 2024. TNF-inhibitors, such as infliximab, etanercept, and
adalimumab, are highly effective in managing moderate to severe psoriasis.
These biologic drugs target and neutralize TNF-alpha, a key cytokine involved
in the inflammatory process of psoriasis. Their superior efficacy in reducing
psoriasis symptoms and achieving rapid clinical improvement has made them a
preferred choice among healthcare providers and patients.
Leading
dermatological associations and clinical guidelines in Japan endorse
TNF-inhibitors as a first-line treatment for moderate to severe psoriasis.
These endorsements are based on extensive clinical trials and real-world
evidence demonstrating the long-term safety and efficacy of TNF-inhibitors. The
strong backing from the medical community significantly boosts their adoption
and usage. TNF-inhibitors are suitable for a wide range of psoriasis patients,
including those who have not responded adequately to conventional systemic
therapies or topical treatments. This broad eligibility criteria expands the
patient base for TNF-inhibitors, contributing to their dominant market share.
Additionally, these drugs can be used in patients with comorbid conditions,
making them versatile treatment options.
The
TNF-inhibitors segment benefits from continuous innovation and the introduction
of new formulations and delivery methods. For instance, advancements in
subcutaneous injection devices and extended-release formulations enhance
patient convenience and adherence to therapy. These innovations improve patient
outcomes and satisfaction, reinforcing the dominance of TNF-inhibitors in the
market. TNF-inhibitors have a well-established safety profile, with manageable
side effects. Long-term studies and post-marketing surveillance have confirmed
their safety, which boosts confidence among healthcare providers and patients.
The favorable risk-benefit ratio of TNF-inhibitors makes them a reliable choice
for long-term management of psoriasis. Pharmaceutical companies in Japan offer
comprehensive patient support programs for TNF-inhibitor therapies. These
programs include financial assistance, educational resources, and adherence
support, which help patients manage their treatment effectively. Such
initiatives reduce the financial burden on patients and improve treatment
adherence, thereby driving market growth for TNF-inhibitors. These factors
collectively contribute to the growth of this segment.
Download Free Sample Report
Regional Insights
Kanto
emerged as the dominated in the Japan Psoriasis Drugs market in 2024, holding
the largest market share in terms of value. The Kanto region, which includes
Tokyo, Yokohama, and Kawasaki, is the most populous and urbanized area in
Japan. This high population density translates to a larger patient pool for
psoriasis treatment. Urbanization also leads to higher healthcare awareness and
better access to medical facilities, driving demand for psoriasis drugs. Kanto
boasts some of the most advanced healthcare facilities in Japan, including
top-tier hospitals and research institutions. These facilities are equipped
with the latest medical technologies and treatment protocols, enabling them to
offer cutting-edge psoriasis treatments. The presence of renowned healthcare
institutions attracts patients from across the country seeking high-quality
care, further boosting the demand for psoriasis drugs in the region. As the
economic center of Japan, Kanto has a higher average income level compared to
other regions. This economic prosperity allows residents to afford advanced and
often expensive psoriasis treatments. Additionally, the concentration of
pharmaceutical companies and research institutions in Kanto fosters innovation
and the development of new and effective psoriasis drugs, which further
strengthens the market.
Kanto
is home to numerous pharmaceutical companies, both domestic and multinational.
These companies engage in extensive research and development activities,
leading to the introduction of innovative psoriasis treatments. The region's
strong pharmaceutical industry not only supplies the local market but also
drives exports, reinforcing its dominance in the psoriasis drugs market. The
Kanto region hosts a vibrant medical community with numerous dermatologists
specializing in psoriasis treatment. Frequent medical conferences, seminars,
and workshops held in the region promote knowledge sharing and the adoption of
best practices in psoriasis management. This strong medical community ensures
that patients in Kanto receive the most up-to-date and effective treatments,
thereby increasing the demand for advanced psoriasis drugs. The Japanese
government, recognizing the importance of addressing chronic conditions like
psoriasis, provides substantial support for healthcare initiatives in Kanto.
Policies that encourage pharmaceutical innovation, coupled with healthcare
reforms aimed at improving patient access to medications, contribute to the
region’s leadership in the psoriasis drugs market. Government-funded programs
and subsidies make advanced treatments more accessible to patients, driving
market growth.
Recent Developments
- In
June 2024- Dermavant Sciences, a biopharmaceutical company focused on
developing and commercializing innovative immuno-dermatology therapeutics,
announced today that Japan Tobacco has secured approval in Japan for tapinarof
cream 1%. This cream is approved for treating adults with psoriasis and
patients aged 12 and older with atopic dermatitis.
- In
December 2023, UCB, a global biopharmaceutical company, announced today that
the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved
BIMZELX® (bimekizumab) for treating adults with psoriatic arthritis (PsA),
non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis
(AS) who have not responded adequately to existing treatments. This new
approval for bimekizumab in Japan builds on its initial approval in January
2022 for plaque psoriasis, generalized pustular psoriasis, and psoriatic erythroderma.
Bimekizumab is the first IL-17A and IL-17F inhibitor approved in Japan for
treating PsA, nr-axSpA, and AS in adult patients.
- In
October 2023, Janssen Pharmaceuticals, Inc., a Johnson & Johnson company,
announced today that it will feature 30 company-sponsored presentations at the
European Academy of Dermatology and Venereology (EADV) Congress, held in
Berlin, Germany from October 11-14, 2023. Janssen will present new data on the
underlying science of psoriasis treatment, including results from the Phase 3b
GUIDE trial that emphasize early intervention with TREMFYA® (guselkumab)
(Abstract #FC08.5), and systemic pharmacodynamic response data for JNJ-2113
from the Phase 2 FRONTIER 1 trial.
Key Market Players
- Eli
Lilly & Company
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Amgen Inc
- Abbvie Inc
- AstraZeneca
- Boeringer Ingelheim International GmbH
|
By
Therapeutic Class
|
By
Treatment
|
By
Region
|
- Tumor
Necrosis Factor Inhibitor
- Interleukin
Inhibitors
- Others
|
- Topicals
- Systemic
- Biologics
|
- Hokkaido
- Tohoku
- Kanto
- Chubu
- Kansai
- Chugoku
- Shikoku
- Kyushu
|
Report Scope:
In this report, the Japan Psoriasis Drugs Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Japan Psoriasis Drugs Market, By Therapeutics Class:
o Tumor Necrosis Factor Inhibitor
o Interleukin Inhibitors
o Others
- Japan Psoriasis Drugs Market, By Treatment:
o Topicals
o Systemic
o Biologics
- Japan Psoriasis Drugs Market, By Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Japan
Psoriasis Drugs Market.
Available Customizations:
Japan
Psoriasis Drugs market report with the given market data, TechSci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Japan
Psoriasis Drugs Market is an upcoming report to be released soon. If you wish
an early delivery of this report or want to confirm the date of release, please
contact us at [email protected]